RoslinCT and Lykan Bioscience, a combined cell therapy manufacturer, announced Tuesday it is adding six processing suites at its Hopkinton facility. Citing industry demand, the MetroWest and Edinburgh, Scotland based contract developer and manufacturing organization will now have 22 processing suites, with 14 in Hopkinton.
RoslinCT and Lykan Bioscience combined in Aug. 2022 to centralize their cell therapy and gene editing capabilities. The new suites will increase facility capacity by 75%, according to Patrick Lucy, president and CEO of Lykan in a Tuesday press release.Â
“This expansion builds on RoslinCT and Lykan’s expertise and marks another significant milestone in our collaboration. The additional capacity at Lykan’s facility in Hopkinton will allow us to continue delivering cutting-edge products, enabling our clients to offer life-changing therapies to patients around the world and meet the increasing demand for innovative therapies,” said Peter Coleman, CEO of RoslinCT in the release.Â
The new suites will be between 105 and 525 square feet, and will meet both U.S. and European regulatory requirements for clinical and commercial manufacturing. The company did not indicate whether this expansion will result in additional hiring.
